Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Mark McIntyre blog

Tokyo, Japan, January 6th , 2020 — Kyowa Kirin Co., Ltd. (TSE: 4151 President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson’s disease (PD) experiencing “OFF” time, has been validated by the European Medicines Agency (EMA) and is now under …